Safura-Luise Heidari

Ms. Safura-Luise Heidari

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
ASAnne-Sophie Winther Svartstein
Anne-Sophie Winther Svartstein
KDKnudsen Andreas Dehlbæk
Knudsen Andreas Dehlbæk
SHSafura-Luise Heidari
Safura-Luise Heidari
LHLine Dam Heftdal
Line Dam Heftdal
MGMarco Gelpi
Marco Gelpi
SNSusanne Dam Nielsen
Susanne Dam Nielsen
(1) Background: Here, we investigate the incidence of mpox and factors associated with vaccine uptake in mainly well-treated men who have sex with men and are living with HIV (MSMWH). (2) Methods: This study included 727 MSMWH from the Copenhagen co-morbidity in HIV infection (COCOMO) study from 1 May to 31 October 2022. Mpox infection and vaccination status were obtained from the Danish Microbiology Database and The Danish Vaccination Register. Vaccination willingness was assessed through an online survey. (3) Results: At a median follow-up of 180 days, 13 (1.8%) participants had laboratory-confirmed mpox infections. Furthermore, 238 (32.7%) had received the mpox vaccine. A sexually transmitted disease (STD) in the preceding two years was associated with a higher risk of mpox infection (hazard ratio 7.1; 95% confidence interval (CI) [1.9–26.9]) and with higher odds of vaccination (adjusted odds ratio 3.1; 95% CI [2.2–4.6]). 401 (55.2%) participants responded to the survey. 228 (57.0%) reported very high vaccination willingness. The self-perceived risk of infection was associated with vaccine uptake. (4) Conclusions: The incidence of mpox was low. A prior STD was associated with both a higher risk of mpox infection and higher odds of vaccination. Despite high-risk sexual behavior and high vaccination willingness, a sizable fraction of participants had not been vaccinated.

27 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
EEEdith Wolder Ejlersen
Edith Wolder Ejlersen
JLJosefine Amalie Dam Loft
Josefine Amalie Dam Loft
MGMarco Gelpi
Marco Gelpi
SHSafura-Luise Heidari
Safura-Luise Heidari
Omid RezahosseiniOmid Rezahosseini
Omid Rezahosseini
KDKnudsen Andreas Dehlbæk
Knudsen Andreas Dehlbæk
Background/Objectives: Influenza and Streptococcus pneumoniae infections are common vaccine-preventable diseases to which people living with HIV (PLWH) may be more susceptible. This study aims to investigate the incidence of confirmed influenza and pneumococcal infections, and to determine the incidence rate (IR) and factors associated with vaccine uptake in a population of virologically suppressed PLWH. Methods: We included 1031 virologically suppressed PLWH from the Copenhagen Comorbidity in HIV Infection (COCOMO) study. Data on infections and vaccinations between 2015 and 2020 were collected from nationwide registries. Incidence rates with 95% confidence intervals (CIs) of confirmed influenza and pneumococcal infections and vaccine uptake were calculated, and predictors of vaccine uptake were explored using logistic regression. Results: The IR of influenza showed variation from year to year and ranged between 0 (95% CI: 0.0, 7.6) and 18.0 (95% CI: 8.2, 34.1) per 1000 person-years at risk with an overall IR of 8.4 per 1000 person-years at risk (95% CI: 5.4, 12.3). The overall IR of pneumococcal infections was 5.5 per 1000 person-years at risk (95% CI: 3.9, 7.5). Among PLWH, 53.2% were influenza-vaccinated at least once, 72.3% and 22.6% of PLWH were vaccinated at least twice and in all six seasons, respectively, while 31% had at least one pneumococcal vaccine. Previous pneumonia or bronchitis, higher body mass index, use of drugs to treat heart conditions, and longer time with HIV were independently associated with vaccine uptake. Conclusions: We found high incidences of confirmed influenza and pneumococcal infections in virologically suppressed PLWH, but vaccine uptake was below recommendations, highlighting the need for improved vaccination counseling.

15 July 2026 in Journal of Infection
Verified
Journal Article
Open access
LRLennart Riemann
Lennart Riemann
LBLena Böger
Lena Böger
CDCarina Dahl
Carina Dahl
TGTimo Gemoll
Timo Gemoll
CTCharisis Totsikas
Charisis Totsikas
CHChristine Happle
Christine Happle
People living with HIV (PLWH) carry increased risk of chronic obstructive pulmonary disease (COPD), yet the underlying mechanisms remain poorly understood. We investigated whether systemic inflammatory profiles differ between PLWH with and without COPD. We analyzed serum samples from 87 PLWH: 38 with COPD and 49 without COPD, matched for age and sex. Inflammatory proteins were measured using the Olink Target 96 Inflammation panel. Modules of co-varying analytes were identified using CytoMod, and associations with clinical features were tested. Key findings were validated using ELISA. A replication analysis was conducted in 158 samples from an independent cohort. PLWH with COPD showed significantly elevated inflammatory markers. CytoMod analysis identified five modules when adjusting for background levels. Two modules were significantly associated with COPD, and comprised molecules involved in tissue damage and repair. Individual molecules including PD-L1, FGF-23, IL6, and others were significantly dysregulated. ELISA validation confirmed significantly elevated levels of IL-10RB, PD-L1, M-CSF, and IL-6 in PLWH-COPD. Key analytes and directional effects were confirmed in an independent cohort. PLWH with COPD exhibit distinct inflammatory signatures characterized by enhanced tissue damage, immune activation, and dysregulated repair mechanisms, providing insights into HIV-related COPD.